Skip to main content

Advertisement

SpringerLink
Log in

Repurposing of IL 33/ST2 Modulating Drugs as a Cardioprotective Agent: A Promising Approach

  • Perspective
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Drug repurposing has emerged as an enigmatic clinical approach in disorders affecting the cardiovascular system. The concept of drug repurposing has become feasible due to an interim in performing trials for new entities in cardiovascular diseases (CVDs) rather than cancer and diabetes. One of the naïve pathologies brought to the forefront was IL-33/ST2. After delving deeply into this pathway, mitigated levels of sST2 (a decoy receptor for IL-33) were found to prevent plaque formation and fibrosis. This novelty demands the identification of novel therapeutic targets. In this study, the chronopharmacology of frequently prescribed conventional cardiovascular medications was evaluated, and a hypothesis on β-blockers and mineralocorticoid receptor antagonists in modulating the IL-33/ST2 pathway was proposed for their ability to upregulate IL-33, which specifically exhibits cardioprotective activity. This future perspective advocates precise influences in aiming for IL-33 as a key factor for repurposing these medications in CVDs that reduce inflammation and help to unravel potential cardioprotective action and promising outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Box 1

Similar content being viewed by others

Data Availability

No specific data used in this study can be availed upon request.

References

  1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272–87.

  2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J Eur Heart J. 2016;37:2129–200.

    Article  PubMed  Google Scholar 

  3. Ringel MS, Shah NA, Baedeker M, Lim CT, Lamichhane A, Schulze U. Occlusion in the flow of new drugs for cardiovascular disease. Clin Pharmacol Ther. 2017;102:246–53.

    Article  CAS  PubMed  Google Scholar 

  4. Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19:79–84.

    Google Scholar 

  5. Kort E, Jovinge S. Drug repurposing: claiming the full benefit from drug development. Curr Cardiol Rep. 2021;23:62.

  6. Abdelsayed M, Kort EJ, Jovinge S, Mercola M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol. 2022;19:751–64.

  7. Chaffey L, Roberti A, Greaves DR. Drug repurposing in cardiovascular inflammation: successes, failures, and future opportunities. Front Pharmacol. 2022;13:1046406.

  8. Gelosa P, Castiglioni L, Camera M, Sironi L. Repurposing of drugs approved for cardiovascular diseases: opportunity or mirage? Biochem Pharmacol. 2020;177:113895.

  9. Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.

    Article  CAS  PubMed  Google Scholar 

  10. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    Article  CAS  PubMed  Google Scholar 

  11. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752–62.

    Article  CAS  PubMed  Google Scholar 

  12. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.

    Article  CAS  PubMed  Google Scholar 

  13. Onódi Z, Koch S, Rubinstein J, Ferdinandy P, Varga Z V. Drug repurposing for cardiovascular diseases: new targets and indications for probenecid. Br J Pharmacol. 2023;180:685–700.

  14. Tual-Chalot S, Stellos K. Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure. Eur Heart J. 2021;42:3783–5.

  15. March-Vila E, Pinzi L, Sturm N, Tinivella A, Engkvist O, Chen H, et al. On the integration of in silico drug design methods for drug repurposing. Front Pharmacol. 2017;8:298.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Iwata H, Sawada R, Mizutani S, Yamanishi Y. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data. J Chem Inf Model. 2015;55:446–59.

    Article  CAS  PubMed  Google Scholar 

  17. Fiedler LR, Chapman K, Xie M, Maifoshie E, Jenkins M, Golforoush PA, et al. MAP4K4 Inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. Cell Stem Cell. 2019;24:579–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. McKeithan WL, Feyen DAM, Bruyneel AAN, Okolotowicz KJ, Ryan DA, Sampson KJ, et al. Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity. Cell Stem Cell. 2020;27:813–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pott A, Rottbauer W, Just S. Streamlining drug discovery assays for cardiovascular disease using zebrafish. Expert Opin Drug Discov. 2020;15:27–37.

    Article  CAS  PubMed  Google Scholar 

  20. Hassan S, Lone MA. Editorial: Genetic disorders and rare diseases: in vitro models for preclinical pharmacological studies and translation. Front Pharmacol. Frontiers; 2023;14:1346648.

  21. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.

    Article  CAS  PubMed  Google Scholar 

  22. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22.

    Article  CAS  Google Scholar 

  23. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol Nature Publishing Group. 2010;10:103–10.

    Article  CAS  Google Scholar 

  24. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–91.

    Article  CAS  PubMed  Google Scholar 

  26. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. The Rockefeller University Press. 2008;205:339–46.

  27. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res Europe PMC Funders. 2010;107:650–8.

    Article  CAS  Google Scholar 

  28. Shao D, Perros F, Humbert M, Caramori G, Price L, Addcock I, et al. Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension? Thorax BMJ Publishing Group Ltd. 2010;65:A70–A70.

    Google Scholar 

  29. Shao D, Perros F, Caramori G, Meng C, Dormuller P, Chou P-C, et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem Biophys Res Commun. 2014;451:8–14.

    Article  CAS  PubMed  Google Scholar 

  30. Thanikachalam PV, Ramamurthy S, Mallapu P, Varma SR, Narayanan J, Abourehab MA, et al. Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases. Cytokine Growth Factor Rev. 2023;71-72:94–104.

  31. Veeraveedu PT, Sanada S, Okuda K, Fu HY, Matsuzaki T, Araki R, et al. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem Pharmacol. Elsevier Inc. 2017;138:73–8.

  32. Firouzabadi N, Dashti M, Dehshahri A, Bahramali E. Biomarkers of IL-33 and SST2 and lack of association with carvedilol therapy in heart failure. Clin Pharmacol Adv Appl. 2020;12:53–8.

    CAS  Google Scholar 

  33. Xia J, Qu Y, Yin C, Xu D. Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction. Cardiol J. 2017;24:188–94.

    Article  PubMed  Google Scholar 

  34. Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta - Mol Basis Dis. 2013;1832:2442–50.

    Article  CAS  Google Scholar 

  35. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL. Soluble concentrations of the interleukin receptor family member ST2 and β-Blocker therapy in chronic heart failure. Circ Hear Fail. 2013;6:1206–13.

    Article  CAS  Google Scholar 

  36. Huang WP, Zheng X, He L, Su X, Liu CW, Wu MX. Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected ST-segment elevation myocardial infarction. Chin Med J (Engl). 2018;131:1282–8.

    Article  CAS  PubMed  Google Scholar 

  37. Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Hear Fail. 2015;3:50–8.

    Article  Google Scholar 

  38. Ren N, Jiang H, Chen S, Du J, Li W, Huo X, et al. Aldosterone receptor antagonist mitigates diastolic heart failure through inhibition of interleukin-33/ST2 signaling pathway. Acta Medica Mediterr. 2021;37:2439–47.

    Google Scholar 

  39. Chen B, Geng J, Gao S-X, Yue W-W, Liu Q. Eplerenone modulates interleukin-33/sST2 signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction. J Interf Cytokine Res. 2018;38:137–44.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful for the kind consideration of our work.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India

    Punniyakoti Veeraveedu Thanikachalam

  2. College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fujairah, United Arab Emirates

    Srinivasan Ramamurthy

  3. Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India

    Prasanna Bharathi Sainath

  4. WILPD - Engineering, (Off campus), Birla Institute of Technology & Science, Pilani, Chennai Center, India

    Bharathi Radhakrishnan

Authors
  1. Punniyakoti Veeraveedu Thanikachalam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srinivasan Ramamurthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prasanna Bharathi Sainath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bharathi Radhakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Punniyakoti V Thanikachalam: conceptualization and drafted the work; Prasanna Bharathi S: made figures and revised the scientific contents; Srinivasan R and Bharathi R: revised the manuscript critically for important intellectual content. All authors approved the version to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Srinivasan Ramamurthy.

Ethics declarations

Ethics Approval

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thanikachalam, P.V., Ramamurthy, S., Sainath, P.B. et al. Repurposing of IL 33/ST2 Modulating Drugs as a Cardioprotective Agent: A Promising Approach. J Pharm Innov 19, 7 (2024). https://doi.org/10.1007/s12247-024-09818-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12247-024-09818-w

Keywords

Search

Navigation